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Abstract
This report describes the identification and bioinformatics analysis of HLA-DR4-restricted HIV-1 Gag epitope peptides, and
the application of dendritic cell mediated immunization of DNA plasmid constructs. BALB/c (H-2d) and HLA-DR4
(DRA1*0101, DRB1*0401) transgenic mice were immunized with immature dendritic cells transfected by a recombinant DNA
plasmid encoding the lysosome-associated membrane protein-1/HIV-1 Gag (pLAMP/gag) chimera antigen. Three
immunization protocols were compared: 1) primary subcutaneous immunization with 1610
5 immature dendritic cells
transfected by electroporation with the pLAMP/gag DNA plasmid, and a second subcutaneous immunization with the
naked pLAMP/gag DNA plasmid; 2) primary immunization as above, and a second subcutaneous immunization with a pool
of overlapping peptides spanning the HIV-1 Gag sequence; and 3) immunization twice by subcutaneous injection of the
pLAMP/gag DNA plasmid. Primary immunization with pLAMP/gag-transfected dendritic cells elicited the greatest number of
peptide specific T-cell responses, as measured by ex vivo IFN-c ELISpot assay, both in BALB/c and HLA-DR4 transgenic mice.
The pLAMP/gag-transfected dendritic cells prime and naked DNA boost immunization protocol also resulted in an increased
apparent avidity of peptide in the ELISpot assay. Strikingly, 20 of 25 peptide-specific T-cell responses in the HLA-DR4
transgenic mice contained sequences that corresponded, entirely or partially to 18 of the 19 human HLA-DR4 epitopes
listed in the HIV molecular immunology database. Selection of the most conserved epitope peptides as vaccine targets was
facilitated by analysis of their representation and variability in all reported sequences. These data provide a model system
that demonstrates a) the superiority of immunization with dendritic cells transfected with LAMP/gag plasmid DNA, as
compared to naked DNA, b) the value of HLA transgenic mice as a model system for the identification and evaluation of
epitope-based vaccine strategies, and c) the application of variability analysis across reported sequences in public databases
for selection of historically conserved HIV epitopes as vaccine targets.
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Introduction
Dendritic cells (DCs) are professional antigen presenting cells
(APCs) which play a critical role in the generation of cellular
immune responses. DCs acquire antigen (Ag) in the periphery and,
upon activation, migrate to lymph nodes where they orchestrate
the generation of Ag-specific CD4
+ and CD8
+ T-cell responses
[1–3]. They are being used extensively as Ag carriers in candidate
therapeutic vaccine strategies for a variety of disease states,
primarily malignancies, to induce specific T-cell responses with
little or no toxicity [4]. Previous studies have been conducted with
DC transfected with mRNA or plasmid DNA [5–9] . Transfection
with mRNA provides robust Ag expression, but mRNA is difficult
to produce, is unstable, and expression is transient [10]. The use of
plasmid DNA transfection provides a more stable gene material
and offers longer expression time, but has a history of poor
transfection efficiency with DCs and low levels of Ag expression.
However, efficient gene transfer into DCs by electroporation has
recently been demonstrated [11–13].
A number of studies have demonstrated that immunization with
DC transfected with mRNA encoding Ag as a chimera of the
lysosomal-associated membrane protein (LAMP-1) and thus
targeted to the endosomal/lysosomal MHC class II compartment
of DCs, can quantitatively and qualitatively influence the
repertoire of epitope-specific T-cell responses [14,15]. LAMP-1
is constitutively expressed at high levels by all nucleated cells,
including immature DCs. DNA vaccines encoding LAMP/HIV-1
gag fusion constructs and delivered by subcutaneous (sc) injection
have been shown to elicit enhanced antibody, CD4
+, and CD8
+
T-cell responses, and prolonged immunological memory to Gag
antigen epitopes [16–18]. In this study, we tested the effectiveness
of immunization of BALB/c and murine H-2 class II-deficient,
HLA-DR4/human CD4 (huCD4) Tg mice with DCs transfected
ex vivo by electroporation with a LAMP/HIV-1 gag DNA plasmid
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previous pLAMP/gag naked DNA immunization. The HLA DR4
Tg mice were used to compare the DR4-restricted T-cell peptide
determinants identified in this study with those of infected
humans. Both immunization protocols included different prime-
boost formulations with transfected DCs as well as naked plasmid
DNA. Additionally, a bioinformatics approach was used to study
the representation and variability of the identified epitopes of all
database recorded HIV-1 clade B Gag T-cell epitopes. These data
provide insight into the efficacy of different vaccine formulations
and delivery, the diversity of Gag HLA DR4 T-cell epitopes, and
criteria for selection of Gag sequences as vaccine targets.
Results
Immunization with pLAMP/Gag-Electroporated
Immature DC Induces Enhanced T-Cell Peptide Epitope
Repertoire and Avidity in BALB/c and HLA-DR4 Tg Mice
We previously have shown that immunization of BALB/c
(H-2d) mice with naked DNA encoding pLAMP/gag elicited a
broader repertoire and more robust Gag-specific T-cell responses
than did immunization with a plasmid expressing the native Gag
protein (p55gag) [16–20]. In this study, we first compared the
T-cell responses of BALB/c mice immunized with immature
DCs transfected by pLAMP/gag DNA in comparison to those
immunized with naked pLAMP/gag DNA. The peptide-specific
T-cell responses were measured by ex vivo IFN-c ELISpot assay
with a library of 123 overlapping peptides encompassing the entire
p55gag sequence. The relative avidity of the epitope peptides was
also evaluated using peptide concentrations varying by two orders
of magnitude in the ELISpot assays (10, 1, and 0.1 mg/mL).
Immunization with pLAMP/gag-transfected DCs followed by a
naked pLAMP/gag boost elicited enhanced IFN-c secreting T-cell
responses with a greater repertoire and apparent avidity than did
the naked pLAMP/gag DNA prime and boost immunization,
particularly at the lower and intermediate peptide concentrations
in the ELISpot assay (Figure 1; Table 1).
The efficacy of immunization with transfected DCs was further
evaluated by immunization of HLA-DR4 Tg mice [21–23] with
the same immunization protocol as applied to the BALB/c mice.
This study had the additional advantage of allowing a comparison
of the data from the transgenic animal model to that obtained
from studies of infected humans and available in public HIV
databases. Splenocytes from the immunized Tg mice were
depleted of CD8
+ T cells and IFN-c secreting T-cell responses
were measured by ELISpot assay as described above. A total of 25
epitope peptides were identified. Similar to the BALB/c study
described herein, immunization with pLAMP/gag-transfected
DCs prime followed by naked pLAMP/gag boost, or alternatively,
pLAMP/gag-transfected DCs prime/Gag peptide boost, elicited a
larger number of T-cell responses with greater avidity than did
immunization with pLAMP/gag prime/boost (Figure 2; Table 2).
Localization and Clustering of the H-2d and HLA-DR4
Epitope Peptides Elicited by pLAMP/Gag Immunization
The ELISpot positive HIV-1 Gag epitope peptides elicited after
immunization with pLAMP/gag by the various formulations were
present as clusters of overlapping peptides at defined sequence
localizations, with the majority of the epitope peptides detected in
assays at 10 mg/mL peptide (Figure 2). The T-cell epitope peptides
of BALB/c mice were present in four regions of 3 to 5 overlapping
sequences comprising 16 of the 19 total epitope peptides (Figure 1;
Table 1). The CD4
+ T-cell epitope peptides of the HLA-DR4 Tg
mice were also clustered in 4 to 5 regions detected with ELISpot
assays containing 10 mg/mL peptide (Figure 2; Table 2). Results of
the different immunization formulations indicated that despite
differences between the immunogen delivery as DC, peptides, or
naked DNA, there was little difference in the localization of the
epitope peptides. DC-mediated immunization enhanced the
breath and strength of the T-cell responses to a group of
immunogenic peptides that included those elicited by immuniza-
tion with naked pLAMP/gag, and did not primarly affect the
selection of the major immunogenic regions.
Comparison of Identified HLA-DR4 Epitope Peptides with
Reported Human DR4 Epitopes
The epitopes of the HLA DR4 Tg mice identified in this study
were compared to the Gag DR4 epitopes of HIV-1 infected
Figure 1. Peptide specificity and relative avidity of IFN-c-secreting HIV-1 Gag-specific T-cell responses in BALB/c mice immunized
with pLAMP/gag-based prime and boost formulations. Mice were immunized subcutaneously with naked pLAMP/gag plasmid 50 mg DNA or
with 1610
5 pLAMP/gag-transfected immature DCs (DC-LAMP/gag), and boosted with naked pLAMP/gag plasmid (lower and upper lines) or Gag
peptides (middle line). Gag peptide-specific T cell responses were measured by ex vivo IFN-c ELISpot assay at peptide concentration of 10 mg/ml
(top), 1 mg/ml (middle), and 0.1 mg/ml (bottom), as described in Materials and Methods. The domain structure of the unprocessed HIV-1 Gag protein,
and the numbering of the corresponding peptides are indicated on the top. Colored boxes indicate peptides eliciting positive IFN-c ELISpot
responses in mice immunized with pLAMP/gag plasmid DNA prime/boost (yellow), DC-LAMP/gag prime and Gag peptide boost (red), and DC-LAMP/
gag prime and pLAMP/gag plasmid DNA boost (black).
doi:10.1371/journal.pone.0008574.g001
T Cell Epitope Activation
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Strikingly, 21 of the 25 peptides that elicited CD4
+ T-cell
responses in DC immunized HLA-DR4 Tg mice overlapped at
least nine consecutive amino acids in 18 of the 19 human HLA-
DR4-restricted HIV-1 Gag epitopes (Figure 3). The reported
human epitopes were detected by multiple methods, including
Table 1. HIV-1 Gag epitope peptides eliciting IFN-c-secreting T-cell responses in BALB/c (H-2d) mice immunized with pLAMP/gag-
based prime and boost formulations
a.
BEI
peptide
HIV Gag peptide
positionsb Amino acid sequencesb IFN-c SFC/ 10
6 total splenocytes
c
DC-LAMP/gag,
pLAMP/gag
DC-LAMP/gag,
Gag peptides
pLAMP/gag,
pLAMP/gag
15 57–71 CRQILGQLQPSLQTG 57612 101654 0 64
20 77–91 SLYNTVATLYCVHQR 913614 248618 65265
49 193–207 GHQAAMQMLKETINE 1078625 600657 748620
50 197–211 AMQMLKETINEEAAE 929639 291617 78566
51 201–215 LKETINEEAAEWDRL 8760 158611 -
56 221–235 GPIAPGQMREPRGSD 6261- -
65 257–271 PVGEIYKRWIILGLN 145695 4 633 2 6 619
66 261–275 IYKRWIILGLNKIVR 124648 2 63-
67 265–279 WIILGLNKIVRMYSP 9965 106619 12069
74 293–307 FRDYVDRFYKTLRAE 186685 3 65-
75 297–311 VDRFYKTLRAEQASQ 23369 122652 6 2 611
76 301–315 YKTLRAEQASQEVKN 138667 6 641 3 2 66
77 305–319 RAEQASQEVKNWMTE 89664 5 635 3 61
78 309–323 ASQEVKNWMTETLLV 4664- -
96 381–395 GNFRNQRKTVKCFNC 24567 102631 8 3 615
97 385–399 NQRKTVKCFNCGKEG 148688 1 654 8 65
98 389–403 TVKCFNCGKEGHIAK 16664 122686 0 66
99 393–407 FNCGKEGHIAKNCRA 128623 7 63-
100 397–411 KEGHIAKNCRAPRKK 60643 1 63-
aAs detected by ex vivo IFN-c ELISpot assay.
bReferring to the HIV-1 HXB2 Gag sequence.
cSFC, spot-forming cells. ELISpot values6SD were obtained from groups of 10 mice immunized with pLAMP/gag-transfected DCs prime and pLAMP/gag plasmid DNA
boost (left column), pLAMP/gag-transfected DCs prime and Gag peptides boost (middle column), and pLAMP/gag plasmid DNA prime and boost (right column).
Negative results are indicated by dashes.
doi:10.1371/journal.pone.0008574.t001
Figure 2. Peptide specificity and relative avidity of IFN-c-secreting HIV-1 Gag-specific CD4 T-cell responses in HLA-DR4
(DRB1*0401) Tg mice immunized with pLAMP/gag-based formulations. Mice were immunized subcutaneously with 50 mg pLAMP/gag
plasmid DNA or with 1610
5 pLAMP-1/gag-transfected immature DCs (DC-LAMP/gag), and boosted with pLAMP/gag plasmid DNA (lower and upper
lines) or Gag peptides (middle line). Gag peptide-specific CD4 T cell responses were measured by IFN-c ELISpot assay using CD8-depleted
splenocytes, at peptide concentration of 10 mg/ml (top), 1 mg/ml (middle), and 0.1 mg/ml (bottom). The domain structure of the HIV-1 Gag
polyprotein is indicated on the top, and the corresponding overlapping peptides are numbered below. Peptides eliciting positive ELISpot responses
in mice immunized with pLAMP/gag plasmid DNA prime/boost (yellow), DC-LAMP/gag prime and Gag peptide boost (red), and DC-LAMP/gag prime
and plasmid DNA boost (black) are indicated below.
doi:10.1371/journal.pone.0008574.g002
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intracellular cytokine staining, and IFN-c ELISpot of CD4 T cells.
In addition, the other epitope peptides of this study that are
clustered but not coincident with the currently described human
CD4 epitopes [peptides no. (position): 62 (245–259), 63 (249–263),
64 (253–267), and 79 (313–327)], suggest the possible presence of
other CD4 epitopes. Only one of the reported human epitopes
(accession no.: 201011), was not matched by those of the DR4
Tg mice.
Representation and Variability of the Identified DR4
Epitope Peptide Sequences
Sequences of the 25 DR4-restricted clade B Gag epitope peptides
of this study were analyzed for their representation (frequency) and
variability in all human HIV-1 clade B Gag sequences listed in the
NCBI Entrez protein database (as of August 2008). Many of the
epitope peptides were evolutionarily highly variable in their
representation in the recorded HIV-1 Gag sequences; 8 were
present in 71–79%; 6 in 50 to 69%; and the remaining 11 in less
than 50% (Table 3 and Table S1). The number of unique variants
for each of the epitope peptides ranged from 51 to a remarkable
627, with as many as 15 amino acid differences per epitope peptide
(Table 3). Many of the individual variants for each epitope peptide
sequence represented a significant percentage of the total
representation ranging, up to 37% (Table S1). However, only
four epitopes (out of 25) had a mutant variant sequence as the
predominant peptide [peptide no. (position): 21 (81–95), 22 (85–99),
78 (305–319), and 79 (313–327)]; in majority of the cases (21 out
Table 3. Representation of identified DR4-restricted T-cell epitope peptides and their variants in reported human HIV-1 clade B
Gag protein sequences, obtained from the NCBI Entrez protein database
a.
HLA-DR4-restricted Gag epitope
peptide
Total no. of
corresponding
sequencesb
Representation
of T-cell epitope
peptide Variants of the T-cell epitope peptides
Representation
of variant
peptides
No. of
unique
variants
% maximum
representation
of individual
variants
c
Maximum no.
of amino acid
variations
37-ASRELERFAVNPGLL-51 3282 2322 (,71%) 960 (,29%) 162 307 (,9%) 15
41-LERFAVNPGLLETSE-55 3479 1660 (,48%) 1819 (,52%) 266 235 (,7%) 15
73-EELRSLYNTVATLYC-87 3655 559 (,15%) 3096 (,85%) 347 427 (,12%) 9
77-SLYNTVATLYCVHQR-91 3601 341(,9%) 3260 (,91%) 415 459 (,13%) 6
81-TVATLYCVHQRIEVK-95 3570 144 (,4%) 3426 (,96%) 627 311 (,9%) 8
85-LYCVHQRIEVKDTKE-99 3578 297 (,8%) 3281 (,92%) 466 426 (,12%) 7
161-EKAFSPEVIPMFSAL-175 1792 1343 (,75%) 449(,25%) 72 248 (,14%) 8
165-SPEVIPMFSALSEGA-179 1839 1327 (,72%) 512 (,28%) 71 259 (,14%) 6
169-IPMFSALSEGATPQD-183 1913 1319 (,69%) 594 (,31%) 86 267 (,14%) 8
233-GSDIAGTTSTLQEQI-247 1508 1196 (,79%) 312 (,21%) 63 140 (,9%) 8
241-STLQEQIGWMTNNPP-255 1489 646 (,43%) 843 (,57%) 133 151 (,10%) 10
245-EQIGWMTNNPPIPVG-259 1489 671 (,45%) 818 (,55%) 126 165 (,11%) 13
249-WMTNNPPIPVGEIYK-263 1585 787 (,50%) 798 (,50%) 105 228 (,14%) 14
253-NPPIPVGEIYKRWII-267 1471 1040 (,71%) 431 (,29%) 78 134 (,9%) 6
257-PVGEIYKRWIILGLN-271 1474 958 (,65%) 516 (,35%) 76 143 (,10%) 5
261-IYKRWIILGLNKIVR-275 1473 1014 (,69%) 459 (,31%) 66 142 (,10%) 5
265-WIILGLNKIVRMYSP-279 1421 1013 (,71%) 408 (,29%) 53 236 (,17%) 5
269-GLNKIVRMYSPTSIL-283 1392 790 (,57%) 602 (,43%) 51 398 (,29%) 5
273-IVRMYSPTSILDIRQ-287 1437 542 (,38%) 895 (,62%) 73 365 (,25%) 5
277-YSPTSILDIRQGPKE-291 1460 545 (,37%) 915 (,63%) 71 380 (,26%) 4
281-SILDIRQGPKEPFRD-295 1455 1007 (,69%) 448 (,31%) 61 307 (,21%) 5
297-VDRFYKTLRAEQASQ-311 1221 883 (,72%) 338 (,28%) 66 118 (,10%) 9
301-YKTLRAEQASQEVKN-315 1117 369 (,33%) 748 (,67%) 84 409(,37%) 13
305-RAEQASQEVKNWMTE-319 1113 430 (,39%) 683 (,61%) 80 370 (,33%) 15
313-VKNWMTETLLVQNAN-327 1095 851(,78%) 244 (,22%) 64 68 (,6%) 3
aExample interpretation of the table: The peptide epitope 37-ASRELERFAVNPGLL-51 was present in 2322 sequences (71%) of all 3282 sequences analyzed
corresponding to the epitope. The remaining 960 sequences (29%) at that position were variants to the epitope, which were made up of 162 unique peptides with the
maximum representation of any of these peptides at 9% (307 peptides) of all the sequences analyzed. The maximum number of amino acid variations betweent h e
epitope and the variants was 15 amino acids.
bTotal No. of HIV-1 Gag sequences corresponding to the T-cell epitope peptide obtained from the NCBI Entrez protein database (as of August 2008). The number of
corresponding sequences for each epitope varies because the database contained both partial and full-length sequences, the consequence of which is that some
regions have more sequence information than others.
cFor each one of the T-cell epitope peptides, the % minimum representation of individual variants was less than 1%.
doi:10.1371/journal.pone.0008574.t003
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representation. There was no specific pattern for the distribution of
the mutant amino acids in the variants (difference of 3 to 15 aa).
Discussion
DCs serve critical roles in facilitating immune responses to foreign
Ag, in particular by promoting efficient Ag presentation and co-
stimulation to CD4
+ T lymphocytes. Although several different bone
marrow2derived cells can present Ag in vitro, the main APCs that do
so in vivo are DCs [24–26]. DCs also engage in cross-presentation of
peptideepitopesto CD8
+T-cellsandcross-priming ofcellsforMHC
class I-dependent Ag presentation [27]. Because of these capacities,
DC-based vaccines are widely considered to be promising strategies
for cancer and persistent pathogen infections such as HIV. This may
be compared to naked DNA vaccines which typically express limited
amounts of Ag largely restricted to inoculation sites, have restricted
access to professional APCs, and poorly activate inflammatory
responses, unless combined with additional genetic adjuvants [28].
Here we have studied the immunization of BALB/c (H-2d) and
HLA-DR4 Tg mice by autologous DCs transfected ex vivo by a DNA
plasmid encoding HIV-1 Gag inserted into the LAMP-1 luminal
domain, or by direct immunization with the naked DNA plasmid.
Immunization by DCs transfected ex vivo is believed to deliver a large
number of Ag-activated DCs to the immunized animal, with greater
antigen presentation to T cells than would occur with direct
immunization by the naked DNA vaccine plasmid. However, the
transfected DCs as the primary immunogen would likely have
limited delivery of antigen to any other cell in vivo, greatly reducing
the transfection of non-professional APCs and MHC class I
dependent presentation of peptide epitopes to CD8
+ cells [29]. This
was likely offset, however, by the subsequent boost with naked DNA
encoding LAMP/gag or with peptides, both of which provide Ag
access to cells for MHC class I Ag presentation. In contrast to
immunization with transfected DC, immunization with the naked
DNA plasmid encoding LAMP/gag results in transfection at the site
of immunization of large numbers of muscle and other non-
professional MHC class I APCs and likely results in relatively large
scale activation of CD8
+ T cells [30]. Targeting of the LAMP/gag
chimera to lysosomes of professional APCs is known to result in
marked co-localization of the fusion Ag with MHC class II
molecules, and activation of both Ag-specific CD4
+ and CD8
+ T
cells [31,32]. An additional factor could be the release of HIV Gag
from cells as exosome-like vesicles [33] which has been shown to
occur in animal model studies [34]. This peculiar property of HIV
gag could represent a significant route for its acquisition by DCs in
vivo in the absence of LAMP-1 targeting.
The epitope-specific T-cell responses to HIV-1 Gag generated
by immunization with either the autologous immature DC
transfected with pLAMP/gag or naked pLAMP/gag was mea-
sured by IFN-c ELISpot assay using a panel of 123 overlapping
Gag peptides encompassing the entire protein. Groups of mice
were primed by sc immunization with LAMP/gag DNA-
transfected DCs or naked LAMP/gag plasmid DNA, and then
boosted with the LAMP/gag plasmid DNA or gag peptide pools.
The consistency of T-cell epitope peptide responses elicited by the
Figure 3. Correlation of known human DR4 CD4 epitopes to ELISpot positive peptides from HLA-DR4 transgenic mice. Previously
published CD4
+ epitopes of HIV infected patients were aligned with IFN-c ELISpot positive peptide from DR4 mice immunized with LAMP/gag
transfected immature DC and plasmid LAMP/gag boost (dark grey bars - known human sequence with HIV molecular immunology database
accession number labeled inside, light grey bars - ELISpot positive peptides with the peptide number labeled inside).
doi:10.1371/journal.pone.0008574.g003
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DR4 Tg mice is evident from the ELISpot assays with 10 mg/mL
peptide. The major differences were the greater fraction of total
peptide repertoire and greater apparent avidity of the peptides in
the ELISpot assay for either MHC or T-cell receptor binding
following the DC LAMP/gag prime-pLAMP/gag boost protocol.
The stronger responses to the DC LAMP/gag-pLAMP/gag
prime-boost can most simply be attributed to an increased number
of antigen presenting DCs following in vitro transfection, or to an
increased level of antigen presentation or access to MHC loading
compartments. Some of the peptides were distinguished by strong
T-cell activation at low peptide dose in all tested groups of either
the BALB/c or HLA DR4 Tg mice at low peptide dose. Other
peptides required higher concentration of peptides in the ELISpot
assay and the response was enhanced in or unique to mice primed
with plasmid DNA-transfected DCs and boosted with peptides or
plasmid DNA. The biological correlates to the differences in the
immune responses to the peptides are not known. However, it can
be expected that specific epitopes may have unique properties. It
has been reported that DCs transfected with interleukin-12 and
tumor-associated Ag-encoding mRNA were found to induce high
avidity cytotoxic T-lymphocytes (CTLs) [35], and that DCs
transfected with RNA encoding tumor antigens resulted in
prolonged Ag presentation and the generation of high-affinity
tumor-reactive CTLs [36]. Other experiments have also suggested
that epitopes that elicit extremely strong T-cell responses may in
fact lead to immune tolerance [37].
The low representation of the epitope peptide sequences and their
high number of variants represent a major issue for the development
of an effective HIV vaccine. The DR4 epitope peptides exhibited
variants with as little as 3 or as many as 15 amino acid differences.
Vaccine strategies based on Gag or possibly any HIV-1 protein as
immunogen may not be effective in preventing natural infection
because of the large number of HIV-1 genomic variants as potential
altered epitope peptides. Subtle amino acid mutational differences of
HLA-restricted T-cell determinants between a vaccine formulation
and a natural infection [38] can dramatically alter the magnitude of
the T-cell response and result in a wide range of effects from
increased immune activation to anergy [39–43]. This may possibly
be in part overcome by selection of epitope peptides that have high
conservation and representation, and where only a minority of
subjects would be infected by a virus with a protein sequence that
differed from the consensus sequence represented by the vaccine
immunogen.Itisevident,however,thattheextremelyhighmutation
rate of the HIV-1 virus represents a severe problem for the
development of an effective vaccine. These issues may be elucidated
by further use of HLA transgenic mice for analysis of T-cell
activation with selected peptides and their variant forms.
In conclusion, the methodology described in this study, the use
of LAMP/gag transfected immature DCs to stimulate an Ag-
specific T-cell immune response in vivo, provides a broadly
applicable strategy for the functional activation of T-cell antigens
for HIV therapeutic vaccines that effectively induce HIV-gag
specific T-cell responses, with increased avidity and repertoire.
The identification of HIV epitopes that represent a large
proportion of the circulating virus population must be included
to develop a HIV vaccine that can stimulate a robust immune
response.
Materials and Methods
Cloning of the pLAMP/Gag DNA Construct
The nucleotide sequences of the HIV-1 clade B HXB2 (NCBI
Accession No. K03455, M38432) that codes for the p55gag Ag
was cloned, with the addition of XhoI and EcoRI restriction sites,
into the p43-LAMP-1 eukaryotic expression vector, between the
LAMP-1 luminal and transmembrane sequences. The p43-
LAMP-1 vector is a pcDNA3.1-based DNA plasmid containing
a cytomegalovirus (CMV) promoter, the LAMP-1 luminal
sequence, the XhoI and EcoRI cloning sites, the LAMP
transmembrane and cytoplasmic sequences, and the bovine
growth hormone polyadenylation sequence, flanked by two
adeno-associated virus inverted terminal repeat sequences [44].
Mice
Murine H-2 class II-deficient, HLA-DR4 (DRA1*0101,
DRB1*0401)/human CD4 (huCD4) Tg mice [45–47] were bred
and maintained in the Johns Hopkins University School of
Medicine Animal Facility. HLA-DR expression and CD4
+
T-cell frequency in the experimental mice were evaluated by
flow cytometry using HLA-DR-FITC and CD4-PE (BD Biosci-
ence Pharmingen, San Diego, CA) conjugated antibodies,
respectively. BALB/c mice were purchased from Charles River
(Wilmington, MA). Mice were housed in specific pathogen-free
colonies and maintained in a helicobacter-negative mice facility.
All animal experiments were performed according to the National
Institutes of Health Guide for Care and Use of Experimental
Animals and approved by Johns Hopkins Animal Care and Use
Committee.
Bone Marrow Dendritic Cell Culture
Murine DCs were generated from the bone marrow using a
protocol slightly modified from Inaba et al. [48]. Briefly, the donor
mice were euthanized by CO2 asphyxiation followed by cervical
dislocation, the femurs and tibias collected, and the muscle tissues
removed with gauze. The bones were placed in a 60 mm dish with
70% ethyl alcohol for 1 min, washed twice with PBS, and
transferred into a fresh dish with RPMI 1640. The bone marrows
were then flushed with 3 ml RPMI 1640 per bone and the viable
cells were counted using a Vi-CELL Cell Viability Analyzer
(Beckman Coulter, Fullerton, CA). The cells were centrifuged at
300g for 10 min, and the supernatant discarded. The cell pellet
was resuspended in RPMI-1640 supplemented with 10% mouse
serum, 2000 U/ml GM-CSF, 100 units/ml penicillin-streptomy-
cin, 2 mM L-glutamine, 50 mM 2-mercaptoethanol, and 1 M
HEPES buffer at 1610
6 cells/mL, transferred into a 24-well plate
(1ml/well), and incubated in a 37uC incubator with a 5% CO2
atmosphere. Fresh medium containing GM-CSF was added every
second day. On day seven the immature DCs were harvested by
collecting non-adherent and loosely adherent cells.
Electroporation of Immature Dendritic Cells
After seven days culture, the immature DCs were collected and
centrifuged at 300 g for 10 min, resuspended in 100 uL of
Nucleofector solution (Lonza Inc, Walkersville, MD) to a final
concentration of 2.5610
5/100 mL, and 5 mg of the pLAMP/gag
plasmid DNA was added to each microcentrifuge tube. The
mixture was transferred to an Amaxa certified cuvette and
electroporated with the preset Nucleofector program Y-001 for
immature DCs. The transfected DCs were then suspended in
400 ml complete media and transferred onto a 48-well plate and
incubated overnight in a humidified 37uC5 %C O 2 incubator.
DC Immunization Protocol
Three experimental immunization groups of 10 mice (5 pools of
2 mice) was immunized and boosted three to four weeks later by
subcutaneous injection at the base of the tail.
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5 DCs transfected with p43LAMP/gag
plasmid (5 mg); Boost: p43LAMP/gag plasmid (5 mg)
Group 2 Prime: same as Group 1; Boost: pooled peptide (1mg/
peptide)
Group 3 Prime: p43LAMP/gag plasmid (50 mg); Boost: same as
prime
Group 4 Prime: 1610
5 DCs transfected with p43GFP plasmid
(5 mg); Boost: p43GFP plasmid (5 mg)
Splenocyte Isolation
Ten days following the boost immunization, splenocytes were
harvested from mice euthanized as previously described. Single
cell suspensions were prepared by manual disruption and
separation through a 70 mm cell strainer. The cells were washed
with complete RPMI (1640 medium supplemented with 10% FBS,
100 units/mL penicillin-streptomycin, 2 mM L-glutamine, 50 mM
2-mercaptoethanol, and 1 M HEPES buffer), centrifuged for
10 min at 300 g at 4uC, and resuspended in 5 ml ammonium
chloride for 5 min at room temperature to lyse the red blood cells.
Then 25 ml complete RPMI-1640 was added to stop the reaction.
The cells were again centrifuged at 300 g at 4uC and the pellet was
resuspended in 10 ml complete RPMI-1640. Cells were counted
with the Vi-CELL Cell Viability Analyzer and adjusted to a
concentration of 1610
7/mL in complete RPMI.
HIV p55gag Synthetic Peptides
A library of 123 overlapping 15 amino acid (aa) peptides
spanning the entire HIV-1 HBX2 p55gag protein, more than 80%
pure, were obtained from Biodefense & Emerging Infections
Research Resources Repository (Manassas, VA). Lyophilized
peptides were dissolved at 1 mg/mL in 20% DMSO and water,
aliquoted, and stored at 220uC.
IFN-c ELISpot Assay
Ex vivo IFN-c ELISpot assays were performed by use of murine
IFN-c ELISpot sets (BD Biosciences) according to manufacturer’s
protocol. For Tg mice, single cell suspensions from freshly isolated
splenocytes in complete RPMI-1640 were depleted of CD8
+
T-cells using antibody-coated magnetic beads (Miltenyi Biotec.
Auburn, CA) according to manufacturer’s protocol. A total of
1610
6 splenocytes diluted into 100 ml complete RPMI-1640 were
added to wells containing individual p55gag peptides. Concanav-
alin A (Sigma-Aldrich, St. Louis, MO), 5 mg/ml, and culture
medium without peptide were used as positive and negative
controls, respectively. Following assay protocol, the plates air-
dried, and the spots counted using a stereomicroscope at 406
magnification with the ImmunoSpot software (CTL analyzer,
Cleveland, OH). The average number of spot forming cells (SFC)
was adjusted for 1610
6 splenocytes.
Evaluation Statistics
The average IFN-c secreting T-cell responses against each
peptide for vaccinated mice were compared by a nonparametric
t test to the background values of control mice primed with a green
fluorescent protein expressing p43 plasmid (p43GFP). The
responses were considered positive when the p value was .0.05
and the average response was .10 IFN-c SFC/10
6 splenocytes.
Negative control assays for mice immunized with the p43-GFP
plasmid DNA commonly gave blank values of 0–10 SFC per 10
6
splenocytes.
Comparison of Identified HLA-DR4 Epitope Peptides with
Reported Human DR4 Epitopes
The epitopes of the HLA DR4 Tg mice identified in this study
were compared to the reported epitopes of HIV-1 infected humans
by performing blastp [49] search with an in house database
(February 2009) of 388 T-helper/CD4
+ epitope sequences,
obtained from the HIV immunology database. BLAST hit
sequences with at least nine consecutive amino acid matches to
the query epitope were extracted for further analysis. All identified
T-helper/CD4
+ epitopes in the HIV immunology database were
retrieved and records with HLA-DRB1*0401 or DR4 restrictions
in the ‘‘Species (MHC/HLA)’’ field were selected.
Diversity Analysis of the Identified DR4 Epitope Peptide
Sequences
A total of 6,403 complete and partial human HIV-1 clade B
Gag protein sequences were retrieved from the NCBI Entrez
protein database records as of August 2008. Multiple sequence
alignment of the sequences was performed by use of Promals3D
[50], which was then manually inspected and corrected for
misalignments. The diversity of each of the identified HIV-1 Gag
DR4 Tg epitope peptide sequence was studied by extracting all the
sequences in the alignment corresponding to the position of the
epitope, except those that contained gaps (-) or any one of the
unresolved characters, including B (asparagine or aspartic acid), J
(leucine or Isoleucine), X (unspecified or unknown amino acid)
and Z (glutamine or glutamic acid). All the extracted sequences
were then analyzed for the representation (frequency) of the
epitope sequence and its variants. Variants are defined as peptides
with at least one amino acid difference from their corresponding
identified epitope.
Supporting Information
Table S1 The representation of HLA-DR4 transgenic mice
epitope peptides and their variants in clade B HIV Gag protein.
Found at: doi:10.1371/journal.pone.0008574.s001 (0.35 MB
DOC)
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